Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Inclusion Criteria: * Non-small cell lung cancer (NSCLC) patients who are eligible for treatment with atezolizumab for approved indications. These include the following: * Locally advanced or metastatic 1st line patients whose tumors have high PD-L1 expression (PD-L1 stained \>= 50% of tumor cells \[TC \>= 50%\] or PD-L1 stained tumor-infiltrating immune cells \[IC\] covering \>= 10% of the tumor area \[IC \>= 10%\]), as determined by an Food and Drug Administration (FDA) - approved test, with no EGFR or ALK genomic tumor aberrations * For the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving * For adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on \>= 1% of tumor cells, as determined by an FDA-approved test * Be willing and able to provide written informed consent/assent for the trial * Be at least 18 years of age on day of signing informed consent * Have detectable disease based on computed tomography (CT) and/or positron emission tomography (PET) scan * Have ready access wifi or cellular data plan * Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale * Ability to comply w…